Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ: IPHA )

1.996 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
From Innate Pharma SA
Via Business Wire
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
From Innate Pharma S.A.
Via Business Wire
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Leadership Change
From Innate Pharma SA
Via Business Wire
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma to Host Virtual KOL Event on Lacutamab
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Innate Pharma 2024 Financial Calendar
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201... 
Via Benzinga
Exposures Product Safety
Innate Pharma Provides Update on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports First Half 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.